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Abstract
Background: In patients with metastatic renal cell cancer, based on limited evidence, increased sunitinib exposure
is associated with better outcome. The survival and toxicity data of patients receiving individualized dose escalated
sunitinib therapy as compared to standard management were analyzed in this study.
Methods: From July 2013, the data of metastatic renal cell cancer patients with slight progression but still a stable
disease according to RECIST 1.1 criteria treated with an escalated dose of sunitinib (first level: 62.5 mg/day in 4/2 or
2 × 2/1 scheme, second level: 75 mg/day in 4/2 or 2 × 2/1 scheme) were collected prospectively. Regarding
characteristics, outcome, and toxicity data, an explorative retrospective analysis of the register was carried out,
comparing treatments after and before July 1, 2013 in the study (selected patients for escalated dose) and control
(standard dose) groups, respectively.
Results: The study involved 103 patients receiving sunitinib therapy with a median overall and progression free
survival of 25.36 ± 2.62 and 14.2 ± 3.22 months, respectively. Slight progression was detected in 48.5% of them. First
and second-level dose escalation were indicated in 18.2% and 4.1% of patients, respectively. The dosing scheme
was modified in 22.2%. The median progression free survival (39.7 ± 5.1 vs 14.2 ± 1.3 months (p = 0.037)) and the
overall survival (57.5 ± 10.7 vs 27.9 ± 2.5 months (p = 0.044)) were significantly better in the study group (with dose
escalation) than in the control group. Patients with nephrectomy and lower Memorial Sloan Kettering Cancer
Center (MSKCC) scores showed more favorable outcomes. After dose escalation, the most common adverse events
were worsening or development of fatigue, hypertension, stomatitis, and weight loss of over 10%.
Conclusions: Escalation of sunitinib dosing in selected patients with metastatic renal cell cancer, especially in case
of slight progression, based on tolerable toxicity is safe and improves outcome. Dose escalation in 12.5 mg steps
may be recommended for properly educated patients.
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Background
Sunitinib malate, an oral multi-targeted tyrosine kinase in-
hibitor (TKI) is considered to be one of the standard first-
line therapeutic options in metastatic renal cell cancer
(mRCC) [1]. It is a small molecule indolinone [2] which
binds directly to the kinase domain of receptor tyrosine
kinases (RTKs) within an adenosine triphosphate (ATP)
binding pocket between two lobes of the KIT kinase do-
main, preventing phosphorylation and activation [3–5]. It
selectively targets RTKs, which are important in RCC.
Sunitinib has direct anti-tumor effects via binding the
unactivated conformation of KIT and via platelet-derived
growth factor receptor alpha polypeptide (PDGFRA) in-
hibition. The dual inhibitor activity against vascular endo-
thelial growth factor receptors 1 and 3 (VEGFR 1 and
VEGFR3), and platelet-derived growth factor receptor beta
polypeptide (PDGFRB) on endothelial and pericyte mem-
branes enhances anti-angiogenesis [6].
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Sunitinib has been approved by the regulatory author-
ities after it had been demonstrated to improve
progression-free survival (PFS), overall survival (OS), ob-
jective response rate (ORR), and quality of life compared
with interferon-alpha in previously untreated metastatic
RCC patients [1, 7–9]. According to the international
guidelines (e.g., NCCN, ESMO, EAU), sunitinib can be
used as first-line treatment in patients with advanced or
metastatic dominantly clear cell histological type RCC
whose condition has good or intermediate prognosis
[10–12]. Sunitinib has become the gold standard first-
line therapy of mRCC in the past decade, and it has been
used worldwide in this patient population in wider indi-
cations as well [10–16].
The therapeutic administration of sunitinib and the
dedicated patient population for this drug would be
changing and would be refined in the near future. The
preliminary results of the presented Checkmate-214
phase 3 trial with respect to mRCC, in which sunitinib
was the comparator of the investigated drugs [17], the
survival rates were more favorable in case of the im-
mune checkpoint inhibitor nivolumab and ipilimumab
combination compared to sunitinib administered alone,
in poor and intermediate risk groups.
The standard treatment schedule of sunitinib is
50 mg for 28 days with a 14-day break [13–15]. Alter-
nate scheduling (2 weeks on/1 week off ) can also be
used to manage toxicity, but currently no robust data
are available supporting it [16]. The dose can be ad-
justed according to the patient’s response to the treat-
ment, but it should be kept within the range of 25 to
75 mg [18]. At higher sunitinib doses, the direct anti-
cancer effect of the drug may be predominant.
Despite the efficacy of sunitinib therapy, the condi-
tion of initially responding patients may progress due
to the acquired resistance. The underlying mechanisms
for that may be the continuous VEGF axis activation
via upstream or downstream effectors [19–22], b-
fibroblast growth factor (bFGF), c-met, interleukin-8
(IL-8), and angiogenic cytokine pathways [23], altered
pharmacokinetics, drug sequestration [24], and epithe-
lial to mesenchymal transition [25]. Drug resistance is
associated with a transient increase in tumor vascula-
ture and epigenetic changes in histone proteins in the
chromatin, which contribute to tumor angiogenesis by
inactivating the anti-angiogenic factors [26]. However,
the drug-induced resistance can be overcome by suniti-
nib dose escalation [26]. If patients tolerate the stand-
ard regimen, the increased sunitinib exposure is
associated with longer PFS, OS, and a higher response
rate [27, 28].
The aim of our study was to analyze the maximal effi-
ciency and the side-effects of escalated dose sunitinib for
metastatic RCC in the everyday practice.
Methods
Patients
An explorative retrospective analysis of a prospective
mRCC register was carried out at the Department of
Oncotherapy University of Szeged, Hungary. 103 pa-
tients with MSKCC (Memorial Sloan-Kettering Cancer
Center) good (0 unfavorable factor) or intermediate risk
(1 or 2 from the following 5 unfavorable factors: 1.
time from diagnosis to systemic treatment < 1 year; 2.
hemoglobin < lower limit of normal level; 3. calcium
> 10 mg/dL or 2.5 mmol/L; 4. LDH > 1.5 x upper
limit of normal; 5. Karnofsky performance status < 80%)
[1, 18] were treated with sunitinib between January 2010
and December 2016. The study was performed in accord-
ance with the Hungarian and the EU drug law and rele-
vant medical and financial guidelines of the Hungarian
health authorities. The study was approved by the regional
ethics committee (registration number WHO 3482/2014).
The patients received first-line sunitinib after having
undergone nephrectomy or kidney biopsy and
embolization if nephrectomy was not feasible. Histo-
logical and staging examinations, such as abdominal
and chest CT (and bone scintigraphy and skull CT if
clinically indicated), were performed before initiating
the therapy.
Sunitinib therapy and dose modifications
Patients received sunitinib monotherapy orally, in six-
week cycles, at a dose of 50 mg once a day for 4 weeks,
followed by a two-week rest period (4/2 scheme) in 94
(91.3%) cases. In 9 (8.7%) cases with advanced age and
concomitant diseases, the therapy was started with a re-
duced dose of 37.5 mg. Physical and laboratory examina-
tions were performed 2 to 4 weeks after the initiation of
sunitinib therapy, and once every 6 weeks thereafter,
while imaging examination, cardiac and thyroid gland
function follow-ups were performed every 12 weeks. Ad-
equate supportive therapy and proactive management of
side-effects were applied. Dose reduction (DR), modifi-
cation of dose scheme (DSM) (2 weeks on/1 week off ),
or therapeutic delay occurred due to the following rea-
sons: grade 3/4 thrombocytopenia, neutropenia, hand–
foot syndrome affecting walking, stomatitis or diarrhea
of grade 3/4, which significantly influenced the nutrition
or resulted in > 10% weight loss, hypertension of grade
3/4 developing despite being on combined antihyperten-
sive therapy. The severity of adverse events was graded
according to the National Cancer Institute Common
Terminology Criteria for Adverse Events Version 4.0
(NCI CTCAE v4.0) [29]. The general condition of the
patients was assessed according to the Karnofsky scale
[30]. PFS and OS were defined from the onset of the
medical treatment to the date of progression based on
RECIST 1.1 or death, respectively. The evaluation of
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tumor response was performed every 12 weeks according
to Response Evaluation Criteria In Solid Tumors
(RECIST) 1.1. Sunitinib therapy was discontinued in case
of progression per the RECIST criteria in all cases (com-
pared to best response). If the CT indicated slight progres-
sion (SP) but still corresponded to stable disease
according to the RECIST 1.1 criteria [31] in patients en-
rolled in the study after June 30, 2013 (study group), a
dose escalation (DE) strategy was started with careful
follow-up if any clinically significant side effect was de-
tected. The dose was elevated first to 62.5 mg, and if a
slight progression was still present or occurred again, to a
level of 75 mg. Patients showing SP before the date of June
30, 2013 were enrolled in the control group (Fig. 1).
Evaluation of the effect of dose escalation
The effects of dose escalation was analyzed on PFS and
OS of both the entire patient population and the pa-
tients showing SP. Two groups of patients with SP were
distinguished considering that the SP occurred before or
after June 30, 2013; patients before that date were
treated with an unchanged standard dose, despite the
presence of SP. After that date, in cases without relevant
side effects, a DE strategy was applied. The outcome was
analyzed according to the characteristics of the patients
of the two groups as well as the side effects and other
factors that could influence the escalation of the dose.
Statistical analysis
The association between PFS, OS and age, and the num-
ber of metastatic organs was analyzed using COX re-
gression. The influence of the therapy-related factors
(dose escalation, dose reduction, therapeutic lines after
sunitinib, nephrectomy, and treatment group), and
patient-related factors (gender, MSKCC score) on PFS
and OS was analyzed with Kaplan–Meier analysis. To
compare the median follow up times between control
and study groups, the Mann-Whitney U Test was used.
To determine the differences between the control and
study groups, independent sample t-test and chi-square
test were used for the continuous and categorical vari-
ables, respectively. To detect the independent role of
nephrectomy and DE on the outcome, multivariate COX
regression was used. All statistical analyses were
performed by using SPSS 20.0 for Windows (SPSS Inc.,
Chicago, IL, USA).
Fig. 1 Flowchart of sunitinib dose modifications. (CG – control group, CR – complete remission, DE – dose escalation, DR – dose reduction, LTF –
lost to follow-up, N – number of analyzed patients, PD – progressive disease, PR – partial remission, RECIST – Response Evaluation Criteria In Solid
Tumors, SD – stable disease, SG – study group)
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Results
Patient characteristics
Out of the 103 patients who participated in the study,
80 (77.7%) were men and 23 (22.3%) were women
(Table 1). The mean ± standard error (±SE) age was
62.27 ± 0.9 (range, 32–80) years, and 84.5% of the pa-
tients had undergone nephrectomy. The mean (±SE)
MSKCC score was 1.7 ± 0.05, and the mean number of
metastatic sites was 2.32 ± 0.11 (range, 1–5). Lungs,
bone and distant lymph nodes were the most frequent
localizations of metastases (Table 1). 68% of the
patients had a comorbidity that required treatment.
Hypertension, other cardiovascular disorders, and
diabetes were the most common diseases.
Hyperthyroidism and well-managed hypertension at the
beginning of the therapy occurred in 5 (4.9%) and 32
(31.1%) patients, respectively. The rate of secondary tu-
mors was relatively high (8.7%) as well as the rate of
primary bone metastasis (45.6%). Mean ± SE value of
baseline LVEF was 61.7 ± 3.2%. The histological type of
the tumors was mainly clear cell renal cell cancer
(ccRCC) in case of all patients, and in most cases pure
ccRCC. No rare variants could be detected, but only
sarcomatoid, papillary and chromophobe morphologies,
and transformations in the ccRCC were present. No
genetic analyses were performed to prove the familial
origin of the renal cancer. The baseline characteristics
of the patients are presented in Table 1.
Table 1 Baseline demographics of all patients and of patients with slight progression
Patients Nall = 103 NSP = 48
Mean age, years ± SE 62.27 ± 0.9 61.76 ± 1.62
Age range, years 32–80
MSKCC score, mean ± SE 1.7 ± 0.05 1.6 ± 0.1
Gender
Male 80 (77.7%) 39 81.3%
Female 23 23 (22.3%) 9 18.7%
Number of patients after nephrectomy 87 84.5% 42 87.5%
Comorbidities
Hypertension 32 31.1% 9 18.8%
Other cardiovascular disorders 12 11.6% 5 10.4%
Diabetes 11 10.7% 4 8.3%
Secondary tumors 9 8.7% 1 2%
Hyperthyroidism 5 4.9% 0 0%
Hematological disease 3 2.9% 0 0%
Psoriasis 2 1.9% 0 0%
Metastases
Mean number of metastatic sites (range) 2.32 ± 0.11 (1–5) 1.79 ± 0.1 (1–3)
Location of metastases
Lungs 84 81.6% 39 81.2%
Bone 47 45.6% 16 33.3%
Distant lymph node 36 34.9% 20 41.7%
Liver 19 18.4% 7 14.6%
Brain 11 10.7% 0 0%
Suprarenal gland 9 8.7% 4 8.3%
Other (peritoneum, pleura, pancreas, local relapse,
contralateral kidney, or thyroid gland)
– ‹8% – ‹4%
Patients with synchronous metastases 94 91.2% 45 93.8%
Histopathological types n %
Purely clear cell renal cell type (ccRCC) 91 88.3% 46 95.8%
ccRCC with sarcomatoid morphology 7 6.8% 1 2%
ccRCC with papillary−/chromophobe−/ both 3 / 2 / 1 2.9 / 1.9 / 1.0% 1/0/0 2/0/0%
ccRCC clear cell renal cell cancer, MSKCC Memorial Sloan Kettering Cancer Center, n number of involved patients, N number of analyzed patients, SE standard error
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Sunitinib dose parameters and efficiency
No dose reduction (DR) had to be applied in 59 (59.6%)
patients (50 mg/day in 4/2 or 2 × 2/1 scheme or 37.5 mg
daily dose administered continuously in 2 cases). First-
level (37.5 mg/day in 4/2 or 2 × 2/1 scheme) and
second-level (25 mg daily dose in 4/2 or 2 × 2/1 scheme)
dose reductions were required during the treatment in
25 (25.3%) and 9 (9.1%) cases, respectively. Sunitinib
therapy had to be ultimately ceased within 12 weeks in 5
(5%) patients due to progression of the disease. The
follow-up of four patients was incomplete; thus, their
data were excluded from the final analyses.
The dosing scheme was modified (DSM) in case of 22
(22.2%) patients. A cycle delay of more than 7 days was
needed in 15 (15.1%) patients because of an infection,
herniotomy, dental intervention, diarrhea, neutropenia,
or cardiac decompensation. Mean ± SE duration of the
delay was 7.8 ± 3.3 days. The median PFS ± SE was 14.2
± 3.22 (95% CI 7.87–20.52) months. Complete remission
as the most favorable tumor response was achieved in 7
(7.1%) cases. Partial remission and stable disease were
accomplished in 31 (31.3%) and 56 (56.6%) patients,
respectively.
In cases of SP, the result of radiological revision ac-
cording to RECIST 1.1 was stable disease in 48 (48.5%)
cases. First-level (62.5 mg/day in 4/2 or 2 × 2/1 scheme)
and second-level (75 mg daily dose in 4/2 or 2 × 2/1
scheme) dose escalations were indicated in 18 (18.2%)
and 4 (4.1%) patients, respectively. The median ± SE dur-
ation of sunitinib therapy was 19.45 ± 2.01 (95%CI
14.87–22.94) months until definition of slight progres-
sion and 7.8 ± 1.55 (95%CI 4.74–10.85) months from
date of SP to progression. The median OS was 25.36 ±
2.62 (95% CI 20.23–30.5), and the median follow-up
time was 24.37 (1.33–93.83) months, respectively. Suniti-
nib therapy is still continued in 10 (10.1%) patients, and
5 patients underwent metastasectomy; their sunitinib
therapy was discontinued and rechallenged in 3 (3%) of
them. After progression on sunitinib therapy, no further
therapy was administered in 30 (30.3%) cases, while in
47 (47.4%) and 5 (5.1%) patients, one and two therapy
lines were applied, respectively.
Factors influencing efficacy
PFS and OS were not influenced by the patients’ age, gen-
der, the number/type of metastatic organ systems, and
dose reduction in the overall population. Patients with
nephrectomy and lower MSKCC scores showed more fa-
vorable outcomes in the studied population (Table 2).
DE was performed in 18 (18.2%) cases among the eval-
uated 99 patients. PFS and OS results were more favor-
able when the dose was escalated rather than in case of
Table 2 Factors influencing the outcome of sunitinib therapy in all patients
Specifications of analyzed
patients N = 99
PFS-HR (95% CI) p OS-HR (95% CI) p
Age 1.012 (0.987–1.038) 0.351 1.007 (0.981–1.035) 0.590
Number of metastatic organs 1.083 (0.891–1.317) 0.423 1.100 (0.896–1.350) 0.364
PFS-HR (95% CI) p OS-HR (95% CI) p
Gender
man/ woman 1 / 1.367 (0.807–2.316) 0.245 1 / 1.388 (0.792–2.435) 0.252
MSKCC score
0 / 1 / 2 1 / 3.770 (1.345–28.435) /
6.693 (1.813–49.061)
0.019 1 / 2.692 (1.355–20.445) /
5.199 (1.713–37.929)
0.023
Dose reduction
Yes / No 1 / 1.492 (0.947–2.506) 0.065 1 / 1.553 (0.963–2.504) 0.071
Nephrectomy
Yes / No 1 / 2.702 (1.508–4.840) 0.001 1 / 3.189 (1.741–5.842) < 0.001
Dose escalation
Yes / No 1 / 2.665 (1.486–4.780) 0.001 1 / 3.157 (1.613–6.179) 0.001
Dose scheme modification
Yes / No 1 / 2.569 (1.437–4.595) 0.001 1 / 2.444 (1.288–4.636) 0.006
Therapeutic lines after sunitinib
2 / 1 / 0 NA NA 1 / 7.731 (2.318–25.787) /
4.043 (1.228–13.311)
0.001
Bold p-values are significant ‹0.05, HR hazard ratio, MSKCC Memorial Sloan Kettering Cancer Center, mOS median overall survival, mPFS median progression-free
survival, NA not applicable, OS overall survival, p p-value, PFS progression-free survival, SE standard error
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patients without escalation. The dosing scheme was
modified in 22 (22.2%) patients. If DSM was performed,
the median PFS and OS were longer than without DSM.
Dose escalation and DSM were independent parameters.
The survival was longer as patients received more thera-
peutic lines after sunitinib treatment (Table 2) (Fig. 2).
The PFS and OS results of patients with SP who
underwent radiological revision and showed to have a
stable disease (48 patients), did not influence the num-
ber of metastatic sites, the MSKCC score, and the dose
reduction. Age and gender of the patients did not influ-
ence the OS. PFS was longer in case of younger male pa-
tients. PFS and OS were more favorable if patients
underwent nephrectomy, in case of DE and DSM
(Table 3).
Influence of dose escalation on effectivity
There were 23 patients in the control group (they
underwent radiological revision before June 30, 2013
and showed slight progression) and 25 patients in the
study group (they underwent radiological revision
after June 30, 2013). The following factors were simi-
lar in the two groups: patients’ age, gender, MSKCC
score, number of metastatic sites, time elapsed from
diagnosis, serum calcium level, LDH, hemoglobin,
Karnofsky performance status, DR and DSM. All pa-
tients underwent nephrectomy in the study group,
whereas it was performed in 17 out of 23 patients in
the control group (p = 0.008). Dose escalation was
only performed in the study group. It could be per-
formed in case of 18 patients (72.0%), but it could
not be carried out in 7 cases (28.0%). Median PFS
(39.7 ± 5.1 vs 14.2 ± 1.3 months (p = 0.037)) and mOS
(57.5 ± 10.7 vs 27.9 ± 2.5 months (p = 0.044)) results
were significantly better in the study group than in
the control group (Table 4). The median follow-up
time of the cohort with slight progression was 37.3
(11.17–93.83) months.
Because of the higher rate of nephrectomy and DE
in study group, a multivariate analysis was performed
to detect the real effect of these factors. Based on a
multivariate COX analysis, both DE (HRDE: 2.12, 95%
CI 1.077–4.181; pDE = 0.030) and nephrectomy
(HRnephr.: 2.47, 95% CI 1.023–6.315; pnephr. = 0.049)
were independent factors of PFS in patients with SP.
In relation to OS, only nephrectomy influenced the
results independently (HRnephr.: 5.02, 95% CI 1.94–
12.98; pnephr. = 0.001) but DE did not (pDE = 0.083).
Fig. 2 Overall survival of patients in four subgroups. Metastasectomy after an effective sunitinib therapy caused the most favorable overall
survival (74.3 months). Median survival of patients with slight progression is longer with dose escalation (58.6 months) than without it
(27.9 months), or the outcome of all other patients (17.9 months) (p‹0.001). (Cum – cumulative, OS – overall survival)
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The impact of dose escalation on the adverse effects
After dose escalation, the most common adverse effects
were the following: worsening or development of fatigue,
hypertension, stomatitis, and weight loss (over 10%)
(Table 5). The most upgraded clinical parameters were
fatigue and development or worsening of hypertension
as a result of the increased sunitinib dose.
Discussion
Sunitinib is one of the most frequently applied first line
therapies in patients with metastatic ccRCC with
MSKCC good and moderate prognoses.
The role of cytoreductive nephrectomy seems to be
equivocal in the era of tyrosine-kinase inhibition. The
results of the SURTIME study were presented by Bex et
al. last year, in which the overall survival and post surgi-
cal complication rates were better with deferred versus
immediate cytoreductive nephrectomy, while progres-
sion rates at 16 and 28 weeks were not significantly dif-
ferent between both sequences [32]. The ongoing
CARMENA study (NCT00930033) may give an answer
to this issue in the near future.
According to the recent knowledge, nephrectomy is
recommended to be performed in patients in good
general condition before the systemic therapy; how-
ever, randomized studies analyzing survival data have
been performed only in combination with INFα ther-
apy [33–35]. In our study, nephrectomy was
performed in 84.8% of the cases, and PFS and OS re-
sults of these patients were more favorable. Each pa-
tient with SP in the Study group (period 2)
underwent nephrectomy (which means that the pa-
tients were fit enough for this operation). It might
have been a potential selectional bias of the compared
cohorts. However, the other parameters and the co-
morbidities of the patients in the two cohorts were
not significantly different.
In our study, PFS was longer than in the registration
study [8]; however, patients with MSKCC poor prognosis
were excluded from our study, but the PFS of our
patients was similar to the excellent international data
[36, 37]. Nowadays, the median OS of patients with
metastatic RCC is longer than 2 years [1], as it can be
seen in our results as well.
One of the most important things in case of a success-
fully optimized medical therapy is appropriate dosing:
the individually titrated, tolerable dose, with the admin-
istration of the maximum daily dose. It is important to
choose the most suitable dosing scheme after taking co-
morbidities into consideration [38]. The recommended
starting dose for sunitinib malate is 50 mg daily for
28 days followed by a 14-day break. Although individual-
ized sunitinib therapy improves the outcome, poorer
outcomes in patients tolerating the standard schedule
treatment without significant toxicity [1, 14] may be the
result of underdosing [27]. Several authors [39, 40] have
Table 3 Factors influencing the outcome of sunitinib therapy in SP cases
Specifications of all patients with slight progression N = 48 PFS-HR (95% CI) p OS-HR (95% CI) p
Age 1.047 (1.008–1.089) 0.019 1.025 (0.982–1.069) 0.265
Number of metastatic organs 1.159 (0.873–1.538) 0.307 1.107 (0.820–1.494) 0.508
PFS-HR (95% CI) p OS-HR (95% CI) p
Gender
man/woman 3.202 (1.473–6.962) 0.003 2.077 (0.891–4.846) 0.091
MSKCC score
0 / 1 / 2 1 / 3.671 (0.474–28.414) /
5.304 (0.709–39.661)
0.176 1 / 2.965 (0.375–23.430) /
3.841 (0.513–28.786)
0.366
Dose reduction
Yes / No 1 / 0.840 (0.450–1.570) 0.585 1 / 0.724 (0.365–1.436) 0.356
Nephrectomy
Yes / No 1 / 3.397 (1.364–8.461) 0.009 1 / 5.583 (2.135–14.601) < 0.001
Dose escalation
Yes / No 1 / 2.383 (1.241–4.578) 0.009 1 / 2.479 (1.185–5.183) 0.016
Dose scheme modification
Yes / No 1 / 2.373 (1.034–5.445) 0.041 1 / 2.583 (1.008–6.709) 0.047
Therapeutic lines after sunitinib
2 / 1 / 0 NA NA 1 / 6.163 (1.582–24.016) /
3.873 (1.130–13.280)
0.032
Bold p-values are significant ‹0.05, HR hazard ratio, MSKCC Memorial Sloan Kettering Cancer Center, mOS median overall survival, mPFS median progression-free
survival, NA not applicable, OS overall survival, p p-value, PFS progression-free survival, SE standard error, SP slight progression
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Table 4 Characteristics and results of patients with slight progression in the control and study groups
Specifications of patients with
slight progression
NSP = 48
Control group Before
June 30, 2013
NCG = 23
Study group
After June 30, 2013
NSG = 25
p
Mean age, years ± SE 62.87 ± 1.73 60.74 ± 1.52 0.358
Gender
male 17 (73.9%) 22 (88.0%) 0.190
female 6 (26.1%) 3 (12.0%)
MSKCC score, mean ± SE 1.61 ± 0.1 1.60 ± 0.1 0.952
Number of metastatic sites, mean ± SE 2.17 ± 0.24 2.36 ± 0.21 0.559
Location of metastases
Lungs 19 (82.6%) 20 (80%) 0.556
Bone 7 (30.4%) 9 (36%) 0.460
Distant lymph node 8 (34.8%) 12 (48%) 0.263
Liver 3 (13%) 4 (16%) 0.549
Suprarenal gland 1 (4.3%) 3 (12%) 0.337
Comorbidities
Hypertension 4 (17.4%) 5 (20%) 0.556
Other cardiovascular disorders 2 (8.7%) 3 (12%) 0.541
Diabetes 2 (8.7%) 2 (8%) 0.663
Secondary tumors 0 1 0.521
Nephrectomy
No 6 (26.1%) 0 (0.0%) 0.008
Yes 17 (73.9%) 25 (100.0%)
Time from diagnosis to initiation of sunitinib
< 1 year 11 (47.8%) 15 (60.0%) 0.289
> 1 year 12 (52.2%) 10 (40.0%)
Hemoglobin level
< normal range 6 (26.1%) 3 (12.0%) 0.190
> normal range 17 (73.9%) 22 (88.0%)
Elevated corrected calcium level
> 2.5 mmol/L 2 (8.7%) 1 (4.0%) 0.468
< 2.5 mmol/L 21 (91.3%) 24 (96.0%)
Elevated LDH level
> 1.5× normal level 2 (8.7%) 0 (0.0%) 0.224
< 1.5× normal level 21 (91.3%) 25 (100.0%)
Elevated corrected calcium level
> 2.5 mmol/L 2 (8.7%) 1 (4.0%) 0.468
< 2.5 mmol/L 21 (91.3%) 24 (96.0%)
Karnofsky performance status
< 80 0 (0.0%) 1 (4.0%) 0.521
≥ 80 23 (100.0%) 24 (96.0%)
Dose reduction rate
No 10 (43.5%) 16 (64.0%) 0.226
Level 1 (37.5 mg) 11 (47.8%) 6 (24.0%)
Level 2 (25 mg) 2 (8.7%) 3 (12.0%)
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reported that both PFS and OS are significantly higher
in patients with at least grade 2 hypertension. As on-
target side effects determine the drug effect, toxicity pro-
file can be used to optimize dosing and treatment sched-
ules individually [41]. According to the meta-analysis of
Houk et al. [28], escalated sunitinib exposure (area
under the curve) is associated with improved clinical
outcomes as well as with an increased risk of adverse ef-
fects. The appropriate management of adverse events is
necessary for effective sunitinib treatment, which re-
quires the active contribution of the satisfactorily in-
formed patient. Based on the above mentioned data,
dose escalation has been applied after the summer of
2013 in cases with slight progression, when RECIST 1.1
results confirmed a stable disease if any clinically rele-
vant side effects occurred. Our idea was to achieve the
optimal titration of sunitinib until the appearance of on
target side effects depending on the tolerable off target
adverse events. The rate of CR according to RECIST in
our studied population was relatively high (7.1%) com-
pared to pivotal phase III trials of sunitinib [8], which
might reflect an outstanding benefit from sunitinib
mainly in patients with low tumor volume in our studied
cohort. After an initial favor tumor response evolving
slight progression can be stopped or be reversible with
dose escalation and adequate titration has been hypothe-
sized. Drug toxicity and efficacy may depend on the in-
terindividual differences in pharmacokinetics,
Table 4 Characteristics and results of patients with slight progression in the control and study groups (Continued)
Specifications of patients with
slight progression
NSP = 48
Control group Before
June 30, 2013
NCG = 23
Study group
After June 30, 2013
NSG = 25
p
Dose escalation rate
No 23 (100.0%) 7 (28.0%) < 0.001
Level 1 (62.5 mg) 0 (0.0%) 14 (56.0%)
Level 2 (75 mg) 0 (0.0%) 4 (16.0%)
Dosing scheme modification
No 19 (82.6%) 18 (72.0%) 0.300
Yes 4 (17.4%) 7 (28.0%)
Therapeutic lines after sunitinib 0 / 1 / 2 (%) 6 (30) / 13 (65) / 1 (5) 3 (15) / 13 (65) / 4 (20) 0.247
mOS after sunitinib therapy 9.33 ± 2.0 9.76 ± 2.5 0.599
mPFS 14.2 ± 1.3 39.7 ± 5.1 0.037
mOS 27.9 ± 2.5 57.5 ± 10.7 0.044
median follow-up time (range) (months) 30.9 (11.2–89.5) 45.7 (13.9–84.5) 0.061
Bold p-values are significant ‹0.05, mOS median overall survival, mPFS median progression-free survival, MSKCC Memorial Sloan Kettering Cancer Center, N number
of analyzed patients, p p-value, SE standard error, SP slight progression
Table 5 New or intensifying adverse effects in patients after dose escalation
New or intensifying adverse
effects NDE = 22
Number of patients (percent)
Any grade Grade 1 Grade 2 Grade 3
All 21 (95.5%) 17 (77.3%) 3 (13.6%) 1 (4.5%)
Fatigue 9 (40.9%) 7 (31.8%) 2 (9.1%) 0
Development / worsening of hypertension 8 (36.4%) 7 (31.8%) 1 (4.5%) 0
Stomatitis 6 (27.3%) 5 (22.7%) 1 (4.5%) 0
Diarrhea 5 (22.7%) 3 (13.6%) 1 (4.5%) 1 (4.5%)
Weight loss 10%≤ 4 (18.2%) 4 (18.2%) 0 0
Hand–foot syndrome 4 (18.2%) 4 (18.2%) 0 0
Eyelid edema 2 (9.1%) 2 (9.1%) 0 0
Hypothyroidism 1 (4.5%) 1 (4.5%) 0 0
Elevation in creatinine level 5 (18.2%) 4 (18.2%) 1 (4.5%) 0
Thrombocytopenia 4 (18.2%) 2 (9.1%) 2 (9.1%) 0
Anemia 3 (13.6%) 2 (9.1%) 1 (4.5%) 0
Neutropenia 2 (9.1%) 1 (4.5%) 1 (4.5%) 0
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pharmacodynamics, and pharmacogenetics [42, 43];
however, Motzer et al. [14] have not found correlation
between sunitinib pharmacokinetic values and the tox-
icity profile. Adelaiye et al. [26] have detected an in-
crease in sunitinib plasma concentration in animals
treated with escalated dose TKI in the drug resistant
group, and also a trend for decreased plasma concentra-
tion after prolonged sunitinib exposure. Gotink et al.
[24] have found 1.7 to 2.5-fold increase in sunitinib con-
centration in resistant tumor cells due to the increased
lysosomal drug sequestration, which was reversible after
the removal of sunitinib from the cell culture. Blood
levels of sunitinib reach a steady state at 10 to 14 days,
and a maximum value on day 14 [27], and disease pro-
gression usually occurs during treatment interruption
[44, 45]. In the retrospective analysis of Bjarnason et al.
[27], an individualized treatment strategy and shorter
treatment break (14 days on and 7 days off ) have re-
sulted in improved PFS and OS as compared to the
standard sunitinib schedule, and the PFS detected in pa-
tients with ccRCC has been one of the best reported for
any TKI. Modified sunitinib schedule is well tolerated
and induces optimal drug exposure [46].
Based on our results, PFS and OS results can be im-
proved by sunitinib dose escalation as by dose scheme
modification in case of patients poorly tolerating the
therapy. As the two patient populations are not the
same, their effects can be considered independent. Dose
escalation can be performed in case of patients with
good general condition, who do not have any relevant
adverse effects. In case of these patients, based on the
prognostic values, the survival rate is potentially better.
Therefore, we compared the two (almost similar) groups
regarding dose escalation, so selection of patients with
better prognosis could not have queried the results. The
effect of dose escalation on PFS and OS was confirmed
during the comparison of the two groups. No significant
difference was found among the number of the subse-
quent therapies and mOS after sunitinib was equal in
two groups as well, which may be because in our coun-
try the availability of more active new regimens was very
limited during our study period.
The rate of adverse events (AE) in our real world dose
escalated patients is lower in the selected cohort than
the AE rate in patients administered the standard dose
in the pivotal trials [8, 9]. It might be partly explained by
the favorable VEGFR inhibitor tolerability and the better
proactive management of toxicity, which may improve
the tolerability of the drug.
Acquired resistance to sunitinib therapy, driven by
several likely mechanisms, is a central issue in the treat-
ment of metastatic RCC patients. However, drug resist-
ance may be reversible, and gradual dose escalation may
restore tumor sensitivity to sunitinib, as reported in
preclinical and clinical studies as well. Adelaiye et al.
[26] have treated mice with patient-derived xenografts
5 days/week with a 40–60-80 mg/kg sunitinib dose in-
crease schedule, and they have found selected intrapati-
ent dose escalation safe, resulting in prolonged PFS due
to a greater and longer effect on tumor regression. Al-
though xenografts initially responsive to 40 mg/kg suni-
tinib developed drug resistance, it could be overcome by
incremental dose escalation. In metastatic RCC patients
on standard schedule sunitinib with early disease pro-
gression, Adelaiye et al. [26] could increase sunitinib
dose from 50 to 62.5 and 75 mg daily, with a 14-day on
and 7-day off treatment scheme to some type of grade 2
toxicity, and they observed clinical benefit in the major-
ity of the patients. As reported by Mitchell et al. [47],
the daily dose of sunitinib can be safely up-titrated to
87.5 mg. According to Gotink et al. [24] and Zama et al.
[48], sunitinib rechallenging in previously resistant pa-
tients also has a therapeutic value. Drug resistance is
also associated with epigenetic changes in histone pro-
teins in the chromatin, which may be reversible upon
DE; thus, epigenetic therapies could be successful in
ccRCC patients [26].
The limitations of our study are, on the one hand, its
retrospective design, that is, an explorative retrospective
analysis of a prospective RCC register, and on the other
hand, the relatively small number of patients involved.
Conclusion
In conclusion, an individual escalated sunitinib therapy op-
timized by toxicity profile in metastatic RCC patients pro-
longs PFS and OS, and it is a safe treatment option with a
moderate increase in adverse effects. Based on our data,
dose escalation in 12.5 mg steps may be recommended for
properly educated patients with slight progression, when
RECIST 1.1 results confirm a stable disease in case any
clinically relevant adverse effects occurred.
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